PFIZER INC → Haleon plc HLNCF

Item 4 of the Schedule 13D is hereby supplemented as follows: Following the closing of the January 2025 Secondary Offering (as defined in Item 6), Pfizer will beneficially own Ordinary Shares (including interests in Ordinary Shares held indirectly through holdings of Restricted ADSs) representing less than 10.0% of the Issuer's outstanding Ordinary Shares. As a result, pursuant to the Pfizer Relationship Agreement, the Pfizer Relationship Agreement will terminate and Pfizer will no longer have the contractual right to nominate representative directors to be appointed to the Board. Mr. Denton previously stepped down from the Board following the closing of the September 2024 Secondary Offering.